Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ONCOTHYREON Inc ONTY

Healthcare Biotechnology
"Oncothyreon Inc is a clinical-stage biopharmaceutical company. It develops and commercializes synthetic vaccines & small molecules that treat the lives & outcomes of cancer patients."

Recent & Breaking News (NDAQ:ONTY)

Oncothyreon Announces Corporate Name Change to Cascadian Therapeutics (NASDAQ: CASC)

GlobeNewswire June 8, 2016

Oncothyreon Presents Phase 1b Results of ONT-380 in Combination with T-DM1 in HER2+ Metastatic Breast Cancer at ASCO

GlobeNewswire June 5, 2016

FibroGen Reports Financial Results for the First Quarter of 2016

GlobeNewswire May 9, 2016

Oncothyreon Reports First Quarter 2016 Financial Results & Provides Corporate Update

GlobeNewswire May 9, 2016

4 Biotech Stocks to Buy at Beaten Down Prices

Accesswire April 27, 2016

Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors at American Association for Cancer Research (AACR) Annual Meeting 2016

GlobeNewswire April 19, 2016

Oncothyreon Appoints Scott D. Myers Chief Executive Officer

GlobeNewswire March 29, 2016

Stocks To Buy: These Are Being Considered on Monday 3/21/2016

Accesswire March 21, 2016

Three Stocks To Watch Friday Afternoon 3/18/2016

Accesswire March 18, 2016

Oncothyreon Reports Full Year and Fourth Quarter 2015 Financial Results & Provides Corporate Update

GlobeNewswire March 14, 2016

Oncothyreon to Present at Cowen and Company 36th Annual Health Care Conference

GlobeNewswire March 1, 2016

Oncothyreon Announces First Patient Dosed in Randomized Phase 2 ONT-380 Combination Trial in Patients with HER2-Positive Breast Cancer

GlobeNewswire February 29, 2016

Oncothyreon Appoints Christopher Henney, Ph.D., D.Sc. as Interim CEO and Expands Board With Additions of Mark Lampert and Gwen Fyfe, M.D.

GlobeNewswire January 11, 2016

Where Investors Are Going - Complementary Research on Crocs, Oncothyreon, Nimble Storage and Rexnord

Accesswire December 21, 2015

Investor Alert: These 4 Stocks Could Be Ready To Rally

Accesswire December 11, 2015

Timing is Crucial, Upside Analysis - Analyst Reports on YRC Worldwide, Crocs, Oncothyreon and Nimble Storage

Accesswire December 10, 2015

Oncothyreon Announces Data for ONT-380 in HER2-Positive Breast Cancer Patients With and Without Brain Metastases at the San Antonio Breast Cancer Symposium

GlobeNewswire December 8, 2015

Oncothyreon Announces Webcast to Review Updated Clinical Data on ONT-380 in HER2-Positive Breast Cancer Patients

GlobeNewswire December 2, 2015

Oncothyreon to Present Updated Data on ONT-380 for the Treatment of HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium

GlobeNewswire November 16, 2015

Oncothyreon Reports Third Quarter 2015 Financial Results

GlobeNewswire November 5, 2015